N eonatal or infantile hypoketotic hypoglycemia with persistent hyperammonemia has been associated with only a few inherited conditions, ie, either defects of the carnitine transport system such as carnitine acylcarnitine carrier deficiency 1 or unusual forms of hyperinsulinism. 2 In affected patients coma and/or convulsions may rapidly develop. Therefore, immediate adequate treatment is required.
The more common cases of isolated hyperinsulinism may be the result of genetic defects in the insulin secretion by the pancreatic ␤ cells. 3 These defects may reside in the plasma membrane sulfonylurea receptor (SUR 1) or an associated potassium channel (Kir 6.2) of the pancreatic ␤ cells. Other causes of hyperinsulinism have also been described. These classic types of hyperinsulinism are not accompanied by elevated blood ammonia levels.
Recently, 10 patients with hyperinsulinism combined with hyperammonemia (HIHA) have been described. 2,4 -10 Both sporadic and dominantly inherited cases were observed. The clinical histories more or less resembled those of leucine-sensitive hypoglycemia, 11 although disorders related with the ammonia disposal have not been reported in the latter condition. The HIHA syndrome has been studied in lymphoblasts. This syndrome was shown to be either the result of hyperactivity of glutamate dehydrogenase (GDH) 10 or impaired inhibition of GDH by guanosine triphosphate (GTP). 5 GDH catalyzes the conversion of glutamic acid into 2-oxoglutaric acid.
In this article, we report our attempts to treat a patient with HIHA in whom the primary defect could be established in liver tissue.
CASE REPORT
The female patient was born as the second child of healthy, nonconsanguineous parents after an uneventful pregnancy and delivery. Neither parent had ever experienced protein intolerance or a tendency to hypoglycemia. Her birth weight was 3840 g (75th centile [P75]), head circumference 36 cm (P75), and Apgar score 8/9. She was admitted on the twelfth day of life because of convulsions and cyanosis, associated with hypoglycemia. During the hypoglycemic episodes, which recurred after discontinuing the parenteral glucose supply, no ketone bodies were found in the urine. Hyperinsulinism was diagnosed on the finding of insulin levels of 28 and 45 U/L at glucose concentrations of 2.8 and 2.7 mmol/L, respectively. When measured at low blood glucose levels, the 24-hour C-peptide excretion was 8.1 nmol (controls: 1.0 -5.5). Blood ammonia was repeatedly elevated and varied from 100 to 200 mol/L in the initial period (neonatal controls Ͻ80). All other routine clinical chemical analyses were normal.
An electroencephalogram did not show any epileptic changes, a computed tomography scan was performed at the age of 2 months and revealed widened ventricles as well as hypodensities of the frontotemporal white matter.
Feeding difficulties became a major clinical problem, necessitating gavage feeding from the age of 6 weeks. She was discharged at 14 weeks. At that time, treatment consisted of diazoxide (2 ϫ 8 mg/day), a high-carbohydrate, and a protein-restricted diet [1.5 g/(kg⅐day)]. Arginine (and later citrulline, 5 ϫ 1000 mg/day) and sodium benzoate (4 ϫ 1500 mg/day) were administered to reduce the blood ammonia levels.
At the age of 2 years, the patient was referred to the University Children's Hospital and her condition was reevaluated. Her length was 84.5 cm (50th centile [P50]), body weight was 15 kg (ϾP90), and head circumference was 48 cm (P50). Her motor development was 7 months delayed; she showed a marked retardation of speech development. Blood ammonia was 312 mol/L (controls: Ͻ50); no further clues to a diagnosis were found. Despite the high ammonia levels no clinical signs of hyperammonemia were noted (such as drowsiness, lethargy or ataxia). A brief trial with an extreme dietary protein restriction [.5 g/(kg⅐day)] did not have any effect on the ammonia levels. Plasma-free carnitine was 12 mol/L (controls: 25-60), total carnitine 13 mol/L (controls: 30 -65). Carnitine supplements (2 ϫ 750 mg/day) were administered. The treatment was adjusted by replacing the oligoglucose formula by uncooked cornstarch. Over the years, the diazoxide treatment was gradually adjusted to the requirements, reaching a dose of 4 ϫ 50 mg/day at the age of 6 years.
As a result of the mitigated carbohydrate intake and the resulting decrease of fat deposits, the patient's adipose appearance markedly improved. However, her development showed a slow progress and the feeding difficulties persisted. These problems led to the decision to install a gastrostoma at age 5. During this intervention, a surgical liver biopsy was taken for diagnostic purposes. After the final diagnosis, treatment with oral supplements of carbamylglutamate (CG) (4 ϫ 500 mg/day) was started. Blood ammonia levels tended to be lower on this regimen, but did not normalize completely. At the age of 6.5 years, her psychomotor development was estimated to be at a level of 4.5 to 5 years (not formally tested).
MATERIALS AND METHODS
Quantitative amino acid analysis was performed with a Biochrom 20 amino acid analyzer (Amersham Pharmacia Biotech, Cambridge, United Kingdom). Organic acids in urine were analyzed by gas chromatography/mass spectrometry (MD800, Fisons, Manchester, United Kingdom) of the ethoximated methyl esters after ethylacetate extraction. Orotic acid in urine was measured using a colorimetric assay. 12 Profiling of plasma acylcarnitines was performed by fast-atom bombardment mass spectrometry after solid-phase extraction and butyl ester formation. 13 All other clinical chemical analyses, including all aspects of insulin homeostasis, were performed by standard methods.
Glutamine synthetase activity was assayed in lymphocytes, leukocytes, and liver homogenate of the patient according to Rowe 14 with slight modifications. The synthesis of 1-14 C-glutamine from 10 mM 1-14 C-potassium glutamate was measured. The reaction mixture contained 10 mM phosphoenolpyruvate, 50 M imidazole-hydrochloric acid (pH 7.2), 10 mM 2-mercaptoethanol, 1 mM ethylenediaminetetraacetic acid (pH 7.2), 20 mM NH 4 Cl, 20 mM MgCl 2 , 10 mM sodium adenosine triphosphate (pH 7.4), 5 g (1 IU) pyruvate kinase and 3 M rotenone. The total volume was 100 L; incubation at 37°C was conducted for 30 or 60 minutes. After stopping the reaction with 400 L of ice cold 4 M imidazole-HCl (pH 7.2) plus 10 M glutamine, the reaction product was isolated on a .5 ϫ 7 cm AG-1x8 (200 -400 mesh) ion exchange column, which was in the acetate form. GDH activity was assayed in a liver biopsy homogenate, essentially as described by Wreszcynski and Colman. 15 The reaction of 2-oxoglutarate with ammoniumchloride forming glutamate and the simultaneous oxidation of NADH was followed spectrophotometrically at 340 nm. Stimulation of the enzyme activity was achieved by adding 200 M adenosine diphosphate (ADP), whereas the effects of the regulatory GTP were studied at concentrations of .01 to 10.0 M.
Ornithine carbamoyltransferase and carbamoyl phosphate synthetase activities were measured in a liver biopsy specimen by spectrophotometric methods.
RESULTS
Because of the persistent hyperammonemia, detailed studies of the urea cycle were performed. Both fasting and postprandial plasma and urine amino acid concentrations were always normal. In particular, citrulline, arginine, and ornithine were not decreased, However, the ratio of plasma glutamine versus blood ammonia was unusually low (Fig 1) , unlike that observed in patients with various urea cycle defects. 16 Plasma glutamate averaged 54 Ϯ 25 mol/L (controls: 30 Ϯ 14), and was therefore not decreased. Urinary orotic acid excretions were inconsistent; at no occasion did we find a striking increase. Urinary organic acids, including 2-oxoglutarate, have always been normal. Cerebrospinal fluid (CSF) amino acids revealed a normal glutamine level (421, 732, and 800 mol/L on 3 occasions, controls: 614 Ϯ 241) and markedly increased levels of ammonia (100, 149 and 161 mol/L, controls Ͻ11). The patient was treated with various regimens aimed at reducing the ammonia level. Neither a drastic reduction of the dietary protein to .5 g/(kg⅐day), nor supplementation with sodium benzoate and arginine or citrulline, led to changes of blood ammonia levels (Fig 2) . In addition, treatment with neomycin remained without effect (data not shown).
At various occasions, simultaneous measurements of blood glucose and insulin were performed, clearly indicating hyperinsulinism. Early morning blood glucose was always in excess of 3 mmol/L; glucose levels during the day went down to 2.7 mmol/L with a concomitant insulin of 45 U/L. On one occasion, blood glucose and insulin were checked before and after a meal. Glucose was 2.8 mmol/L before and 3.5 mmol/L 2 hours after the meal; simultaneous insulins were 28 and 101 U/L, respectively.
The activities of hepatic carbamoyl phosphate synthetase and ornithine carbamoyl transferase were 463 nmol/(h⅐mg protein) (control: 587) and 36.9 mol/ (h⅐mg protein) (control: 45.5), respectively; both values were normal. Glutamine synthetase was assayed in leukocytes and liver, which resulted in values of Relationships between blood ammonia and plasma glutamine in a patient with a regulatory defect of GDH on conventional treatment (OE), on treatment with CG (‚), and in some patients with ornithine carbamoyltransferase deficiency (ࡗ).
.175 nmol/(min⅐mg protein) and 7.15 nmol/(min⅐mg wet weight) respectively. Control values for leukocytes and liver were .115 and 3.41, respectively.
The results of the GDH assay in liver are shown in Fig 3 . Under standard conditions with ADP stimulation, the patient had a normal activity [874 nmol/ (min⅐mg protein), controls 472-938 (n ϭ 3)]. After addition of the inhibitor GTP, this activity decreased more slowly than in the control. Half-maximum inhibition was reached at a GTP concentration of 3.9 mol/L (control mean: .32). Histologically, the liver tissue was normal; there were minimal signs of fibrosis. GDH in fibroblasts was normal [19.4 nmol/ (min⅐mg protein); controls 7.9 -26.8 (n ϭ 3)]. The GTP inhibition was not tested in these cells.
Following the diagnosis, the patient was given a trial with oral CG (4 ϫ 500 mg/day). This treatment was based on the hypothesis that she might suffer from a shortage of glutamate necessary for the synthesis of N-acetylglutamate. Blood ammonia levels were regularly checked during 10 months of follow-up and were found to be consistently lower than before the onset of the treatment (Fig 2) .
DISCUSSION
Recurrent periods of hypoglycemia in infancy without the concurrent availability of alternative energy substrates such as ketone bodies or lactate, represents one of the most important metabolic abnormalities in young children. The same applies for hyperammonemia. A relatively mild increase of blood ammonia levels for short periods of time presumably leads to cerebral damage. Our patient, having only a moderate mental retardation, has had hyperammonemia with ammonia levels in blood and CSF of 100 to 300 mol/L for 6 years in combination with episodically occurring nonfasting hypoketotic hypoglycemia. The latter was in fact the first presenting symptom, accompanied by convulsions. Subsequently hyperinsulinism was diagnosed and this was treated successfully with diazoxide. It was clearly shown that the hypoglycemias were most prominent after a protein-containing meal, similar to the observations made in leucine-sensitive hypoglycemia. 11 As there were no diagnostic clues to the hyperammonemia, treatment was originally directed at alleviating the symptoms by administrating citrulline (originally arginine) for stimulation of the urea cycle, and sodium benzoate for the direct removal of ammonia in the form of hippurate. When we found the aberration in the GDH, implying that in this patient the function of the urea cycle was not compromised, conventional treatment was stopped, and replaced by CG treatment.
Recently, the HIHA syndrome has been identified. 2 Not long thereafter, Stanley et al 5 disclosed regulatory mutations of the GDH gene in some of the patients. Thus far, 3 out of 10 patients, whose clinical history has been published, showed the GDH insensitivity toward GTP in lymphoblasts. The patient reported by Yorifuji et al 10 had a different mutation resulting in a permanent hyperactivity of GDH. No studies in liver were reported. Our data originating from liver tissue show that the basal GDH activity in the patient was normal, in accordance with the lymphoblast findings in sporadic cases. 5 In contrast, the basal GDH-activity in familial cases was moderately decreased. The half-maximum inhibitory concentration of GTP in the patient's liver was approximately 10-fold higher than in control liver tissue. This difference was more pronounced than previously found in the patients' lymphoblasts. 5 Presumably, GTP is present in hepatic tissue at a level that is sufficient to inhibit normal GDH. Mutant GDH-needing a much higher concentration of GTP for its inactivation-is supposed to be fully active when the GTP level is not decreased. There are only a few conditions in which the intracellular GTP concentrations are decreased, eg, hypoxanthine phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome) or purine nucleoside phosphorylase deficiency. Neither of these conditions is associated with a deranged GDH activity leading to hyperinsulinism or hyperammonemia.
Hepatic glutamine synthetase activity in our patient's liver was increased. This may be considered as a compensatory mechanism for the removal of ammonia. However, glutamine synthetase is a highaffinity, low-capacity enzyme and is apparently not capable of removing all excess ammonia. The CSF ammonia levels in our patient were quite high, although accompanied by normal glutamine levels. This result again raises the question of ammonia/ glutamine toxicity to the brain. We have the impression that a single elevation of brain ammonia-without glutamine-showed a less deleterious effect on the brain than a combined increase. Hyperammonemic rats, treated with the glutamine synthetase inhibitor methionine sulfoximine, had less brain edema than untreated hyperammonemic rats. 17 Other reports have shown that brain glutamine synthetase is a saturable enzyme and that ammonia encephalopathy progresses only after saturation of this enzyme. 18 It remains to be established whether brain glutamine synthetase in the present patient was actually exhausted. We do not have information about CSF ammonia levels in patients with urea cycle defects.
The clinical spectrum of HIHA, as deduced from our patient and the literature, 2,4 -10 is rather uniform. None of the patients was severely retarded. In general, moderate mental retardation or even normal development was reported. Convulsions-possibly the result of hypoglycemia-were invariably the presenting symptom. Although symptoms are expected to start in the first week of life, most patients were detected between 2 and 7 months. Blood ammonia levels were comparable in all patients, ranging from 75 to 350 mol/L. None of the authors reported abnormalities of plasma amino acid profiles. There were 2 reports on increased 2-oxoglutarate levels in the urine. 8, 9 It was not mentioned whether these patients had a decreased sensitivity of GDH inhibition by GTP. So there seems to be some biochemical heterogeneity of the HIHA syndrome. Thus far, all patients with a proven defect of GDH had a normal 2-oxoglutarate excretion, including the patient with a permanent hyperactivity of GDH reported by Yorifuji et al. 10 Treatment of the hyperinsulinism varied from simple diazoxide administration (as in the present patient) to subtotal pancreatectomy. It has been shown that glutamate stimulates insulin secretion in rats. 19 The mechanism of this reaction is not entirely clear, but an enhanced oxidation of glutamate by GDH may be a contributing factor. 5 Recently, it has been shown that insulin secretion can be stimulated by leucine, which activates GDH. 20 The differential diagnosis of infantile nonketotic hypoglycemia has been extended. It is now clear that in every case of suspected hyperinsulinism blood ammonia levels should be determined, preferably together with plasma amino acids. The HIHA syndrome may prove to be less rare than originally believed.
Herbal Vitamins: Lead Toxicity and Developmental Delay
ABSTRACT. A case of lead poisoning from an Indian herbal vitamin is presented. The patient who was developmentally delayed was given an herbal vitamin from India to strengthen his brain. The tablet contained large amounts of lead and mercury, leading to significant lead burden. Vulnerability of families and lack of awareness of health care professionals of dangers of unknown herbal supplementation are discussed. Pediatrics 2000; 106:600 -602; herbal vitamins, lead poisoning, developmental delay.
ABBREVIATIONS. EDTA, ethylenediaminetetraacetic acid; BAL, dimercoprol. L ow levels of lead ingestion can lead to cognitive deficits and even long-lasting neurodevelopmental deficits. 1 In the United States the most common source of lead is paint, whereas, in other countries, folk remedies are a significant source. 2 Families with developmentally delayed children are always seeking ways to improve their child's status. This quest makes families especially vulnerable to nonstandard medical intervention and to folk remedies. Many immigrant families are acculturated to non-American remedies. Many of these products have become available and are being used in the United States.
We present a case of chronic lead poisoning in the United States in an Indian child who had an established neurodevelopmental delay. His mother was giving him a natural medication to strengthen his brain.
CASE REPORT
S.P. is a 5-year-old Indian boy with static encephalopathy, seizures, and developmental delay from neonatal asphyxia. He was referred to a hematologist for persistent anemia (hemoglobin: 9.2 g/dL) without basophilic stippling, refractory to iron therapy. Initial investigation revealed normal iron stores and normal hemoglobin electrophoresis. To complete the workup, a blood lead level was obtained, which was 86 g/dL. He was admitted to Childrens Hospital Los Angeles for chelation with calcium disodium ethylenediaminetetraacetic acid (EDTA) and dimercoprol (BAL). On physical examination he was alert and active but nonverbal. He was able to stand with support but not ambulate and had no focal neurologic defects. Skeletal and abdominal radiographs revealed no lead lines and no gastric lead particles. His lead level at the end of the chelation was 25.6 g/dL. A 24-hour-urine collection (1245 mL) on day 3 of chelation revealed a lead level of 4480 g/L or 5578 g/24-hour (normally none detectable).
The mother who is well-educated and whose English is excellent, initially denied any exposure to lead or use of any folk medications. On further investigation, the mother had been giving S.P. a Tibetan Herbal Vitamin, in the form of tablets, 3 times per day for the past 4 years of his life. A traditional medicine healer told the parents that these tablets were pure medicinal herbs and plants that were prepared according to ancient Tibetan pharmacological traditions. These tablets were said to be free from any harmful or toxic substances and would actually promote brain growth and improve his mental capabilities. The tablets were produced in India and each was individually wrapped (Fig 1) . The tablets were analyzed by the Los Angeles County Environmental Toxicology Laboratory for lead, arsenic, cadmium and mercury content (Table 1) . It was estimated that S.P. ingested approximately 63 g of lead over the 4-year period. The radiographs of the tablets (Fig 2) were consistent with high lead and mercury content. The 24-hour-urine sample (1245 mL) was also analyzed for mercury (23 g/L; 28.64 g/24-hour) and arsenic (undetectable). Blood level of mercury was undetectable at Ͻ.5 g/dL, and blood arsenic was .2 g/dL (range: 0 -3.0 g/dL). Public health investigation of the home was negative for other sources of lead.
He was followed as an outpatient and chelated with succimer without incidence. Seven months after his first admission, his blood level was 76 g/dL and he was readmitted for EDTA and BAL chelation. On day 2 of chelation he had a 1-minute tonic clonic seizure. On day 2 random urinary lead was 2310 g/L and his blood lead level on discharge was 41.3 g/dL. During the next 4 years S.P. underwent a total of an additional 6 chelations with succimer when his lead levels were Ͼ45 g/dL. He had no other complication of chelation and after 4 years, his latest lead level was 24.5 g/dL. He has maintained his growth parameters and made developmental progress, achieving ambulation with minimum assistance and he understands simple directions but remains nonverbal.
DISCUSSION
Alternative medicine and folk remedies are widely used and accepted by the general public. It is estimated that in 1990 $13.7 billion was spent on unconventional therapy. 3 Many academic centers have started programs to study and teach the use of alternative forms of therapy. When traditional therapies and medications cannot cure or significantly improve a chronic condition, families and patients are motivated to try alternative approaches. Children with developmental disabilities are especially vulnerable to the introduction of alternative therapies and medications. Past movements such as megavitamin therapy for retardation 4 and the Doman-Delacato technique for brain-damaged children 5 are examples of alternative interventions which were widely used in the United States without proven efficacy. Families in ethnic communities that have a tradition of alternative medicine and folk remedies will seek and support their use and availability in the community.
In our patient's case, the pressure on the family to use traditional medication arose from both the immediate family and from the community that had a great deal of experience and faith in the use of traditional medications from India. In discussing this with the mother, the perceived efficacy of these individually wrapped and colorful vitamins was enhanced by their designation as a Tibetan herbal medication.
In India, a form of traditional medicine called Ayurveda is usually made of vegetable products, occasionally from animal products and less often from metals and minerals. 2 The metals usually consist of lead, mercury, arsenic or, rarely, gold. Analysis of the patients' tablets demonstrated a variable and inconsistent amount of lead and mercury in each tablet. Although previous reports have identified Indian herbal medications as a source of lead, mercury, and arsenic poison, this is not widely appreciated by the lay population or medical community. 6 -9 The vitamins had been obtained directly from a relative in India, costing approximately $40 for a 3-month supply. The mother was told it was formulated by a physician who was close to the Dalai Lama. The mother was very compliant with all traditional therapeutic interventions as she was with administering and securing a steady supply of the vitamin.
S.P.'s baseline developmental delay made the detection of the lead toxicity especially difficult. The effect of lead exposure during brain development has been well-documented. 1 The impact on S.P. of this level of toxicity over 4 years, in the context of a prior neonatal asphyxia, is not quantifiable. Two months after chelation the patient was able to walk with minimal support and was more communicative. Within 6 months of stopping the herbal vitamin, and after chelation, his mother and grandmother felt that he made significant progress in social interactions characterized by more awareness and joy of others, and responsiveness to directions. The persistence of the high lead levels after multiple chelations is not surprising given the estimated 63 g of lead ver, headache, and myalgias, although there are no consistent physical findings. 4 -6 Laboratory hallmarks are neutropenia, thrombocytopenia, and mildly elevated liver transaminases.
The diagnosis of HGE can be confirmed by finding cytoplasmic inclusion bodies (morulae) in granulocytes on a Wright-stained blood smear. Typically, morulae are found in 1% to 6% of granulocytes, 1 although a sensitivity as high as 80% has been reported. 6 Polymerase chain reaction (PCR) to the 16S rDNA sequence has been shown to be rapid, sensitive (86%), and specific (100%). 7 However, PCR testing is not widely available. At the present time, the diagnosis of HGE is most often confirmed by either a fourfold rise between acute and convalescent sera in the indirect fluorescent antibody (IFA) titer to E equi or a single titer Ն1:80. 8 The following case is a very young patient with HGE who had an unusual presentation with acute abdominal pain.
CASE REPORT
A 5-year-old girl presented to the emergency department with a 2-week history of fever and a 2-day history of abdominal pain. There was no vomiting or diarrhea. Another physician had begun treating her with amoxicillin 1 week before for presumptive Lyme disease. There was no history of a tick bite or erythema migrans and her Lyme antibody titers obtained at that time were subsequently reported to be negative. In the emergency department her physical examination was notable for a temperature of 103°F and right lower quadrant tenderness on deep abdominal palpation. Laboratory results included a normal urinalysis, a hemoglobin of 11.2 g/dL, a hematocrit of 32%, a white blood count of 13 400/mm 3 (59% neutrophils, 7% bands, 26% lymphocytes with rare atypical forms, 7% monocytes, and 1% eosinophils), and a platelet count of 287 000/ mm 3 . A blood culture was obtained. The pain resolved without treatment and she was discharged.
She returned to the emergency department about 12 hours later with a temperature of 103.6°F, pallor, abdominal distension, and diffuse abdominal tenderness. A repeat complete blood count was significant for a hemoglobin of 9.1 g/dL, a hematocrit of 27%, a white blood cell count of 8000/mm 3 (59% neutrophils, 5% bands, 26% lymphocytes, and 10% monocytes), and a platelet count of 278 000/mm 3 . The serum electrolytes, prothrombin time, partial thromboplastin time, and a urinalysis were all normal. The aspartate aminotransferase (AST) was minimally elevated (42 U/L), but the alanine aminotransferase (ALT) was normal (36 U/L). Abdominal radiographs and a computed tomography (CT) scan of the abdomen with intravenous contrast were significant for mild hepatosplenomegaly. In view of the persistent high fever, specimens were obtained for serum antibodies to B burgdorferi, E chaffeensis, and the HGE agent, as well as for PCR testing for the 2 causative agents of human ehrlichiosis. The patient was admitted to the hospital.
The next day, the white blood cell count was 8900/mm 3 (68% neutrophils, 26% lymphocytes, and 6% monocytes), the platelet count was 298 000/mm 3 , and an abdominal ultrasound revealed fluid-filled loops of bowel in the right lower quadrant without any free fluid. Intravenous ceftriaxone therapy was initiated. On the third hospital, day the fever, abdominal pain, and distension persisted, and guarding and rebound were noted on abdominal palpation. A repeat abdominal CT scan with oral contrast showed distended loops of small and large bowel without any masses or free fluid. In view of a concern about a possible perforated appendix, an exploratory laparotomy was performed. At surgery, mild nonspecific serositis of the vermiform appendix was found along with a 7-mm lymph node, which subsequently was reported to show nonspecific reactive changes. Postoperatively, her electrolytes and liver function tests were normal (AST: 38 U/L; ALT: 31 U/L), but the white blood cell count had decreased to 3600/mm 3 (69% neutrophils, 29% lymphocytes, and 2% monocytes) and the platelet count was 195 000/mm 3 . The following day (hospital day 4), the New York State Department of Health laboratory reported that the PCR was positive for the presence of HGE agent 16s rDNA and negative for E chaffeensis. Treatment with doxycycline was started and the patient was afebrile the next day.
Subsequently, the acute polyclonal IFA for E equi was reported as nonspecific, but a convalescent specimen obtained 23 days later was positive, with a titer of 320. Four months after the hospitalization the patient was well. At that time her IFA for E equi immunoglobulin G (IgG) was positive (1:512), but the immunoglobulin M (IgM) was negative (Ͻ1:20). Both IgG and IgM IFA titers for E chaffeensis were negative.
DISCUSSION
This case has several unusual features. First, to our knowledge, this the youngest patient reported with documented HGE. 4, 5 The diagnosis was confirmed by the elevated IFA to E equi, the positive PCR for the HGE agent, and the increase in IFA E equi IgG titer between the acute and convalescent specimens. The vast majority of cases of HGE have been reported in adults, with very few diagnosed during the first 2 decades of life. This is in sharp contrast to Lyme disease, in which the incidence is much higher in children than adults. There is no clear explanation for this age discrepancy, despite the fact that the same vector spreads the agents that cause both HGE and Lyme disease.
Second, although many of the patient's symptoms were typical for HGE, there have been no previous reports of HGE mimicking acute abdominal pain in any age patient. In fact abdominal symptoms are unusual, although Wallace et al 5 did report 3 patients with gastrointestinal hemorrhages.
Finally, our patient did not manifest the spectrum of laboratory abnormalities typically seen in adults with HGE. 6 She did have leukopenia, but her platelet count remained normal and she had only a minimal, transient increase in her AST. Once other young patients with HGE are reported, it will be interesting to see whether the clinical presentations are different in children and whether they develop the characteristic laboratory abnormalities noted in older patients. If HGE is suspected, prompt treatment with doxycycline is indicated, pending laboratory confirmation. 9, 10 
